All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-Lewis Y chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human Lewis Y. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-Lewis Y antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of gastric cancer.
CAR Construction : Fig.3 Histogram of flow cytometry based binding of MB311 and MB314 to purified Natural Killer (NK) cells. A human (Fab)'2 fragment was used as control. For detection a phycoerythrin (PE)-labeled anti-human F(ab') fragment was used Roucka, M., Zimmermann, K., Fido, M., & Nechansky, A. (2016). Application of lectin array technology for biobetter characterization: Its correlation with FcγRIII binding and ADCC. Microarrays, 6(1), 1. |
CAR Construction : Fig.1 Binding of MB311 to the Lewis-Y positive tumor cell line SKBR-3 was determined by flow cytometry. Geometric Mean fluorescence intensity (MFI) was plotted vs. the logarithm of the antibody concentration and fitted using a sigmoidal four parameter fit using GraphPad Prism 4 software for calculation of EC 50 values. Kircheis, R., Halanek, N., Koller, I., Jost, W., Schuster, M., Gorr, G., ... & Nechansky, A. (2012, July). Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. In MAbs (Vol. 4, No. 4, pp. 532-541). Taylor & Francis. |
CAR Construction : Fig.2 SKBR-3 target cells and effector cells (PBMCs from a healthy volunteer donor) at an E:T ratio of 25:1 were incubated with 74 ng/ml of MB311 for FACS analysis. Intracellular Expression of tumor necrosis factor (TNF) by CD14+ cells, but not by CD3+ or CD56+ cells. SKBR-3 target cells and effector cells. Kircheis, R., Halanek, N., Koller, I., Jost, W., Schuster, M., Gorr, G., ... & Nechansky, A. (2012, July). Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. In MAbs (Vol. 4, No. 4, pp. 532-541). Taylor & Francis. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-Lewis Y (MB311) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP8397). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION